Cellenkos, Inc.

Cellenkos is a clinical stage biotechnology company developing allogeneic, off-the-shelf immune T regulatory (Treg) cell therapy products to offer anti-inflammatory effects and long-lasting immune modulation to address inflammatory and autoimmune diseases. Our CRANE® Platform allows for selection and enrichment of a subset of umbilical cord blood-derived Tregs tailed to a specific disease and supports our robust pipeline spanning rare autoimmune blood disorders, oncology, neuro-degenerative diseases and inflammatory pulmonary disease. Our Treg cell therapies do not require HLA matching, can be manufactured quickly and administered in an outpatient setting. Cellenkos was founded with the licensing of a proprietary umbilical cord blood T-Regulatory (Tregs) cell therapy platform from MD Anderson Cancer Center.